421 karma · joined January 15, 2024
“ The Interventions Testing Program (ITP) is a peer-reviewed program designed to identify agents that extend lifespan and healthspan in mice. Investigators at any university, institute, company, or other organization are invited to recommend interventions for testing by submitting an application before the February deadline each year. Testing is carried out in the genetically heterogeneous UM-HET3 mouse stock at three sites — the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center at San Antonio.”
https://www.nia.nih.gov/research/dab/interventions-testing-p...
If you think you have ADHD, try getting evaluated by a clinician. It’s not hard to do. A good clinician can go over the range of behavioral and medication options and assess for comirbidities like autism.
The next onion layer will be credulous Fox viewers. But I’m even less clear on how we do that.
Utility of the study is to evaluate potential AI sensitivity if used for mass fully automated screenings using mammography data. But says NOTHING about the CRUCIAL false positive rate (no healthy controls) and NOTHING about AI vs. human performance.
See my main comment elsewhere in this threat.
In nearly half the false negatives from both the mammogram and DWI datasets, the cancer was categorized as occult by two breast radiologists, meaning the cancer was invisible to a trained eye. The AI model's non-occult false negative rate on the mammography data is 19.3%.
For that 19.3% figure, see Table 2: 68 non-occult in AI-missed cancer, 285 non-occult in AI-detected cancer.
This study did not compare the AI to a radiologist on a mixed set of healthy and cancer images.
With CRISPR, it took a long time to figure out how to reliably edit just the gene you want and acceptably minimize off-target edits, including by delivering the therapeutic to just the organ affected and getting the dose and release right.
The public is understandably leery about experimental medical techniques. If they had killed this newborn child with CRISPR therapy, then it might have set created a backlash delaying translation of this technique for years, possibly decades.
In biomedicine, we’re always looking for therapies that approximate the level of precision control available in software. Unfortunately, it’s never more than an approximation, and our ability to measure and predict the size of that error is always limited. That is why the field moves slowly.
Companies can get a METHOD-OF-USE PATENT (MOU) on an old drug for a new INDICATION.
This gives them the exclusive right to LABEL AND MARKET that drug for that indication for a period of time.
I however, doctors can prescribe and pharmacists can substitute generics for the new indication, regardless of the MOU.
For a company to profit off an MOU, they strategically need to create a new FORMULATION. This is a new dose or delivery mechanism (extended release, topical, etc). A new formulation can be protected with conventional patents that go beyond an MOU.
With an MOU + patent on a new formulation, the company has a brand where they are the only ones allowed to make the new formulation and the only ones with a product approved to be marketed for the new indication.
Getting FDA approval for the new brand is not the main hurdle for the company. To get insurers to pay the premium they want over the cost of existing treatment options, they have to show it’s safer or more effective than those existing options. Otherwise insurance will block it.
In principle, this means that repurposing should only enable companies to profitably repurpose off patent off label applications if they can provide a real patient benefit.
Whether this is the best or most efficient way to promote this kind of innovation, or whether it works as well in practice as it would seem in theory, is a separate question.
But I am a pedantic person who prefers to focus on the literal statements in text rather than the perceived underlying emotional current. So I’ll pedantically plod through what she actually said.
She’s dealing with two dimensions of divorce: who initiated it (husband, wife, or collaborative), and whether it was surprising or unsurprising.
That gives several possibilities, but she lists three. What unifies them is that they are all written from the perspective of the abstract woman undergoing the experience.
1. Woman initiated, surprise unspecified.
2. Collaborative, so assume unsurprising.
3. Man initiated, surprising (her situation).
She doesn’t claim this covers all possibilities. The point of that bit is just to emphasize that divorces are different, and to object to treating them as a genre for wellness AI slop.
Here is the original text containing that part so others can easily form their own opinion.
“I also object to the flattening of the contours of my particular divorce. There are really important distinctions between the experiences of women who initiate their own divorces versus women who come to a mutual agreement with their spouses to end the marriage versus women, like me, who are completely blindsided by their husbands’ decisions to suddenly end the marriage. All divorces do involve self-discovery and rebuilding your life, but the ways in which you begin down that path often involve dramatically different circumstances.”
Wasted motion and power saps your time, energy, and motivation. It obscures your vision. It creates unnecessary risk. It decreases your awareness and adaptability.
Examples from my own life: - Teach kids to self-assess using an explicit rubric, instead of delivering feedback yourself every step of the way.
- Move slower and use the minimum power possible when doing chores.
- Jog more slowly and stay in zone 2, where you feel like you can go forever.
- Determine the smallest software performance test scale that makes the issue you’re trying to resolve reliably apparent.
- Resolve as much uncertainty as you can about new software features through separately scripted spikes before attempting to orchestrate them in the full codebase.
- Invest passively in index funds.
- Strip down presentations and pause a few seconds after most sentences. That lets the message sink in, gives you space to decide if you need to say more, and gives the audience a chance to respond if you’re not addressing their confusion effectively.
“ Using transaction-level data on US congressional stock trades, we find that lawmakers who later ascend to leadership positions perform similarly to matched peers beforehand but outperform them by 47 percentage points annually after ascension. Leaders’ superior performance arises through two mechanisms. The political influence channel is reflected in higher returns when their party controls the chamber, sales of stocks preceding regulatory actions, and purchase of stocks whose firms receiving more government contracts and favorable party support on bills. The corporate access channel is reflected in stock trades that predict subsequent corporate news and greater returns on donor-owned or home-state firms.”
A wonderful city like Montreal can drive enough demand for housing to overcome red tape, and still be building far far less than what would satisfy demand. A less attribute city with lower demand for housing may build less due to lower demand, despite having less red tape.
Trust the economists on this one.